NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

NANOBIOTIX reported Phase 1 data for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 heavily pre-treated patients with anti-PD-1-resistant melanoma. The study showed a 41.7% overall response rate, 75% disease control rate, and 17.8 months median overall survival, with an acceptable safety profile. Exploratory analysis identified IL-1β as a key cytokine linked to treatment-induced anti-tumor immunity, warranting further evaluation in randomized clinical trials.